|
Incidence of venous thromboembolism among medical inpatients receiving enoxaparin versus UFH prophylaxis by dosage and duration of prophylaxis received |
|||||
| Outcome (N [%]) |
|||||
|
|
|||||
| Prophylaxis Received/Dosage or Days |
N |
% of Patients |
DVT |
PE |
VTE (DVT and/or PE) |
|
|
|||||
| Dosage: |
|||||
| Enoxaparin |
|||||
| 30–40 mg |
186 |
38.8% |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| 50–60 mg |
293 |
61.2% |
8 (2.7) |
0 (0.0) |
8 (2.7) |
| UFH |
|||||
| 5,000-<10,000 IU |
414 |
14.5% |
47 (11.4) |
8 (1.93) |
52 (12.6) |
| 10,000 IU |
2,221 |
78.0% |
109 (4.9) |
23 (1.04) |
121 (5.4) |
| >10,000–15,000 IU |
214 |
7.5% |
7 (3.3) |
1 (0.5) |
7 (3.3) |
| Prophylaxis days: |
|||||
| Enoxaparin |
|||||
| 1–2 days |
74 |
15.4% |
4 (5.4) |
0 (0.0) |
4 (5.4) |
| 3–4 days |
36 |
7.5% |
2 (5.6) |
0 (0.0) |
2 (5.6) |
| 5–6 days |
123 |
25.7% |
2 (1.6) |
0 (0.0) |
2 (1.6) |
| > 6 days |
246 |
51.4% |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| UFH |
|||||
| 1–2 days |
831 |
29.3% |
109 (13.1) |
22 (2.7) |
120 (14.4) |
| 3–4 days |
227 |
8.0% |
21 (9.25) |
2 (0.9) |
23 (10.1) |
| 5–6 days |
608 |
21.4% |
15 (2.5) |
4 (0.7) |
15 (2.5) |
| > 6 days |
1,171 |
41.3% |
18 (1.5) |
4 (0.3) |
22 (1.9) |
|
Bold indicates p for trend <0.05 | |||||
McGarry et al. Thrombosis Journal 2006 4:17 doi:10.1186/1477-9560-4-17 |
|||||